author-photo

Michael R. Kurman

Princeton University

34

Papers

357

Citations

Citation Trend

Filter By

Papers (21) Sort By

Journal Conference Others

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1-Year Results from an Open-Label Phase 2 Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (2)
The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

2019 Haematologica
Show All
- Source
- Cite
- Save
Citations (30)
Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

2019
Show All
- Source
- Cite
- Save
Citations (0)
TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY: S869

2019
Show All
- Source
- Cite
- Save
Citations (0)